Last reviewed · How we verify
NCT07113366
Efficacy of Jelly Fig (Ficus Awkeotsang Makino) Extract for Atopic Dermatitis
Phase 1 trial testing FAE cream in Atopic Dermatitis (AD) in 30 participants. Completed in 30 November 2024.
1 June 2024
Quick facts
| Lead sponsor | Kaohsiung Veterans General Hospital. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 May 2024 |
| Primary completion | 1 June 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- FAE cream — full drug profile →
- Placebo
Conditions studied
- Atopic Dermatitis (AD) — all drugs for Atopic Dermatitis (AD) →
Sponsor
Kaohsiung Veterans General Hospital.
Who can join
12 and older, any sex, with Atopic Dermatitis (AD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is designed to evaluate the efficacy and safety of a topical formulation containing Ficus awkeotsang Makino extract (FAE), derived from jelly fig, in participants with mild to moderate atopic dermatitis. Ficus awkeotsang is a traditional plant native to Taiwan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07113366
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis (AD)
Currently open trials in the same condition.
- NCT07146971 — Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis · Phase 1 · recruiting
- NCT07235384 — A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participan · Phase 1 · recruiting
- NCT07259343 — Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization · NA · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
- NCT07105488 — A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
Other Kaohsiung Veterans General Hospital. trials
Trials by the same sponsor.
- NCT07278024 — Postbiotic Intervention on Vaginal Microbiota · NA · completed
- NCT07051265 — Effect of Transcutaneous Electrical Nerve Stimulation or Acupressure on Pain in Patients With Head and Neck Cancer · NA · enrolling by invitation
- NCT06777758 — Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments · Phase 4 · recruiting
- NCT06803199 — Effects of LH and FSH on Metabolic Regulation in Cumulus Cells · NA · recruiting
- NCT06946888 — Effects of Acupressure on Nurses' Psychological Distress, Depression, Job Stress, Occupational Burnout, and Resilience · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07113366 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaohsiung Veterans General Hospital.
- Last refreshed: 8 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07113366.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing